The "Elevate" by MAPS Podcast

Post-approval safety studies have traditionally been cumbersome and expensive, and safety study sites are likely to mirror those used in clinical trials, leading organizations to potentially miss safety signals in populations beyond those that typically participate at trial sites. Here we speak with Stefan C. Weiss, MD, Managing Director, Dermatology at OM1 about a transformation in the way we conduct safety studies — relying on EMR patient data overlain with technology to create a more accurate and equitable view of post-market safety.

As technology changes the ways we engage with external stakeholders, the skills we need to manage these interactions are changing, as well. Here we speak with Jen Millard, Vice President of Field Medical at IQVIA, about emerging competencies for external engagement. This episode is sponsored by IQVIA. 

Patient communities continue to mobilize and play an increasingly important role by influencing many elements of the drug development journey and subsequent patient access and support activities. This input ranges from natural history studies, recruitment in clinical trials, understanding burden, contributing to Health Technology Assessments and co-creating educational resources that enable shared decision making and adherence support. Given Medical Affairs stakeholders have similar reach across drug development and commercialization it is logical that this function plays a central role in an organization’s patient-first thinking and strategy. To achieve this, Medical Affairs stakeholders will need to develop thoughtful and impactful strategies that not only build the trust of patient communities but also their internal colleagues.  Here we discuss patient-centricity strategies and actions with Gavin Jones, Global Advisor Rare Disease, OPEN Health, Jenny Ghith, Senior Director, Omnichannel Strategy and Innovations Lead, Pfizer, and Brittany Wolf, Director, Patient Centricity Lead, Pfizer. 

This podcast series focuses on how digital is transforming scientific communications.  In this, our second episode this season, we'll be discussing open access in medical publishing from the biopharma perspective.

In this Opening Doors episode of the Medical Affairs Professional Society podcast series, Elevate, we speak with Áine Prendergast, Medical Science Liaison in Oncology with Ipsen. Hear about Áine's path into the profession and learn important advice that can help you find a first MSL position.

In this second podcast in this series, we will discuss delivering constructive feedback.

On today's episode of the MAPS "Elevate" podcast, we're discussing the use of Real-World Evidence to understand and possibly intercede in treatment-resistant depression and why is it especially difficult to develop treatments against resistant depression using the traditional structure of R&D-led clinical trials.

This podcast series focuses on how digital is transforming scientific communications.  Season 2 Episode 1 will focus on the struggles and successes of compliance in Medical Communications.  Season 2 Episode 2 will focus on the journal publishing industry, discussing how medical journal publishing is transforming and what changes we might see in the future.  Season 2 Episodes 3 and 4 will focus on open access and how we can make scientific information more accessible and open access more transparent.Description and Objectives:Our podcast objectives are for listeners to better understand:·        Compliance issues and considerations facing publication professionals,·        The transparency complexities encountered by publication professionals·        And concerns related to the use of publications in downstream deliverables

Opening Doors episodes of the MAPS Elevate Podcast Series give Medical Affairs professionals the opportunity to tell the story of how they found their way into the profession and to offer advice to others seeking Medical Affairs positions. Here MAPS co-founder, Kirk Shepard, speaks with Niha Yerneni, Medical Scientific Affairs Manager at Ironwood Pharmaceuticals about joining Medical Affairs and, among other ideas, whether a person with recent postgraduate degree (MD, PhD, PharmD) can be successful in immediately seeking a position in industry or if fellowship or other industry training opportunities are necessary gatekeepers for entry.

With the evolving role of Medical Communications in Medical Affairs, greater partnership and integration in Medical Strategy Planning is key to improve overall Medical Affairs outcomes. Enhanced collaboration between these groups drives strong MedComms execution, leading to increased awareness in the HCP, payer, and regulatory communities. During these podcasts, experienced Medical Strategy and Communications leaders will discuss how you can structure roles and responsibilities, KPIs, and best practices to increase synergy between teams.Learning ObjectivesDefining key performance indicators Best practices for measuring success of the Medical Strategy and Medical Communications strategyShare experience on insights communication between the two groups to refine strategy